FDA Approves Amgen And Allergan's MVASI ™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer

Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab) First Ever Biosimilar to Fight Cancer Approved by FDA THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved by the FDA. MVASI is approved for the treatment of five types of cancer, including in combination with chemot...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news